Résumé
To find the effect of quetiapine on lipid peroxidation and serum total antioxidant status [TAS] in schizophrenic patients. The subjects comprised 27 schizophrenic patients and 27 healthy volunteers. Clinical symptoms for the patients were assessed in Brief Individual Psychiatry Rating Scale [BPRS] items. The patients were treated with quetiapine [200-500 mg/day] orally for 8 weeks then reevaluated after the treatment. Blood samples from the patients were taken before and after quetiapine treatments. Other blood samples were taken from healthy subjects as a control group. Serum was obtained and analyzed for malondialdehyde [MDA] and TAS. Base time and after 8 weeks of quetiapine treatment showed a significant decrease in BPRS score in the schizophrenic patients. Serum MDA was significantly higher in the schizophrenic patients [difference = 124.1% of control] than controls. The parameter decreased significantly after quetiapine treatment by 16.9% compared with before treatment values. Serum TAS, in the schizophrenic patients, was significantly lower [38.4%] than controls. Quetiapine increased serum TAS significantly by 21.1%. Quetiapine treatment significantly increased body mass index [BMI] by 2.9%. Quetiapine depressed lipid peroxidation, and raised serum TAS in schizophrenic patients. The change in these parameters by quetiapine may play a role in its therapeutic activit